Insulin resistance *per se* drives early and reversible dysbiosis-mediated gut barrier impairment and bactericidal dysfunction

Dalale Gueddouri 1, Michèle Caüzac 1, Véronique Fauveau 1, Faïlla Benhamed 1, Wafa Charifi 1, Lucie Beaudoin 1, Matthieu Rouland 1, Florian Sicherre 1, Agnès Lehuen 1, Catherine Postic 1, Gaëlle Boudry 2, Anne-Françoise Burnol 1,3, Sandra Guilmeau 1,4

**ABSTRACT**

Objective: A common feature of metabolic diseases is their association with chronic low-grade inflammation. While enhanced gut permeability and systemic bacterial endotoxin translocation have been suggested as key players of this metaflammation, the mechanistic bases underlying these features upon the diabesity cascade remain partly understood.

Methods: Here, we show in mice that, independently of obesity, the induction of acute and global insulin resistance and associated hyperglycemia, upon treatment with an insulin receptor (IR) antagonist (S961), elicits gut hyperpermeability without triggering systemic inflammatory response.

Results: Of note, S961-treated diabetic mice display major defects of gut barrier epithelial functions, such as increased epithelial paracellular permeability and impaired cell-cell junction integrity. We also observed in these mice the early onset of a severe gut dysbiosis, as characterized by the bloom of pro-inflammatory Proteobacteria, and the later collapse of Paneth cells antimicrobial defense. Interestingly, S961 treatment discontinuation is sufficient to promptly restore both the gut microbial balance and the intestinal barrier integrity. Moreover, fecal transplant approaches further confirm that S961-mediated dybiosis contributes at least partly to the disruption of the gut selective epithelial permeability upon diabetic states.

Conclusions: Together, our results highlight that insulin signaling is an indispensable gatekeeper of intestinal barrier integrity, acting as a safeguard against microbial imbalance and acute infections by enteropathogens.

© 2022 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Keywords** Insulin resistance; Gut barrier; Dysbiosis; Antimicrobial defenses

1. INTRODUCTION

One of the hallmarks of obesity and associated type 2 diabetes (T2D) is the occurrence of a chronic low-grade inflammation [1–5]. While this subclinical inflammatory state has long been considered to pave the way for insulin resistance, the mechanistic bases for this metaflammation remain partially understood. Compelling evidence has now linked the enhanced systemic inflammatory tone that is observed upon obesity with adipocyte hypertrophy and associated dysregulated adipokine secretion profile, as well as macrophage infiltration into adipose tissue [6–8]. However, more recent investigations have also brought to light some intestinal dysfunctions, such as enhanced gut permeability and dysbacteriosis-mediated endotoxemia, as potential key players in this feature [9].

The gastrointestinal tract is a specialized organ, which nurtures dynamic interactions with a highly complex environment in order to maintain a homeostatic steady state. Under healthy conditions, the luminal gut microbiota ensures vital roles, such as digestion, development of host immune system, and defense against pathogens, but concomitantly represents a threat of infection. Therefore, intestinal cells collectively ensure, through a two-layer organization, a selective barrier function, by allowing an efficient transcellular transport of nutrients, while rigorously preventing the flow of immune-stimulatory bacterial products across the epithelium. Achieved by epithelial cells, the physical barrier surface shapes the microbiota composition and prevents bacterial adhesion partly through the bactericidal activity of Paneth cells and the production of mucus by goblet cells. In parallel, it also regulates the paracellular diffusion to the host tissues through cell–cell junctional complexes. Beneath the intestinal epithelium, the deep functional barrier that involves immune cell populations of the *lamina propria* discriminates between indigenous microorganisms and enteropathogens and coordinates an adapted immune response [10]. While disruption of gut barrier integrity enables opportunistic bacterial endotoxin translocation into the vasculature, the importance of impaired intestinal permeability in the pathogenesis of obesity-related metabolic alterations and T2D was first demonstrated by the...
pioneering study of Cani et al. [11]. Indeed, by mimicking the enhanced trans-epithelial permeability and systemic influx of Gram-negative bacteria-derived lipopolysaccharide (LPS) that are observed upon high-fat diet-induced obesity, as well as in obesity and T2D mice models (db/db) [12,13], metabolic endotoxemia was identified as a key contributing factor in the initiation of dysregulated inflammatory tone, body weight gain, and diabetes onset. Moreover, reduced endotoxemia and metabolic improvement following antibiotic treatment of both high-fat diet-fed and ob/ob mice further suggested that gut dysbiosis induced by obesity could be a primary defect involved in the onset of gut hyperpermeability [11,14]. A lower phylogenetic diversity with a loss of commensal bacteria and a bloom of pathobionts was indeed reported upon obese conditions [15,16].

While most studies have focused on the emergence of gut dysbiosis and its deleterious intestinal outcomes upon obesity and associated diabetic conditions, induction of insulinopenia by treatment of lean mice with streptozotocin (STZ) was also reported to trigger intestinal microbial imbalance and alterations of various intestinal barrier components [17–19], indicating that blunted insulin action and concomitant hyperglycemia might be at play independently of adiposity. Interestingly, rather than obesity, hemoglobin A1c (HbA1c), indicative of an individual’s three-month average plasma glucose concentration, was also associated with the systemic influx of microbial products in humans [17]. At the mechanistic level, STZ-induced hyperglycemic states per se were proposed to contribute to enhanced gut permeability, through glucose metabolism and transcriptional reprogramming in intestinal epithelial cells, independently of the onset of dysbiosis [17]. However, STZ intracellular uptake by GLUT2 [20], the expression of which in enterocytes is enhanced by STZ treatment [21,22], as well as STZ potency to act as an antibiotic against gram-negative bacteria [23], suggest that this diabetic model may have important limitations when investigating intestinal outcomes, as STZ could directly alter both epithelial cells functions and gut microbiota composition.

Therefore, in order to kinetically identify the consequences of insulin sensitivity changes on gut barrier integrity in the absence of obesity, we used a lean mouse model of reversible insulin resistance. The infusion of S961, a selective antagonist of the insulin receptor (IR), which rapidly induced systemic insulin resistance concomitantly to hyperglycemia and hyperinsulinemia, resulted in gut hyperpermeability associated with a modest local inflammation, and discontinuation of the treatment with S961 was sufficient to promptly and totally reverse this phenotype. At the mechanistic level, our study revealed that among the various components of the gut barrier, the major alterations were the early onset of a severe gut dysbiosis, as characterized by the bloom of pro-inflammatory Proteobacteria, and the later collapse of Paneth cells antimicrobial defense. Of note, fecal transplantation approaches further revealed that such S961-mediated microbial imbalance contributes at least partly to the outbreak of enhanced gut permeability upon hyperglycemic conditions. In conclusion, the present study demonstrates that, independently of obesity, global insulin resistance plays a critical role in reshaping a deleterious gut microbiota, thereby impairing epithelial integrity, which could contribute to the increased risk of the chronic inflammatory response observed in metabolic diseases.

2. MATERIAL AND METHODS

Animals and treatments. All procedures were carried out according to the French guidelines for the care and use of experimental animals and were approved by the “Direction départementale des services vétérinaires de Paris”. ALZET® mini osmotic pumps were implanted subcutaneously in eight-week-old male C57Bl/6 J mice to infuse either S961, an insulin receptor (IR) peptide antagonist (Novo Nordisk) (20 nmol/week), or PBS, as vehicle control, at 0.5 μl/h for 1 week as previously described [24] (PBS and S961 groups). In order to reverse the blockade of insulin signaling, pumps were removed after 7 days of treatment, and mice were studied 7 days after removal of the pumps (groups revPBS and revS961). The various experimental groups were housed in separate cages. Stools were collected and stored at −80 °C for subsequent analyses. For IR downstream signaling analyses, insulin (5 U/kg) was injected i.p. following a 4 h fast, and mice were sacrificed after 10 min. Tissue samples were immediately dissected, frozen in liquid nitrogen, and stored at −80 °C until further analyses. The intestinal segments were flushed with cold PBS, longitudinally opened, and the gut mucosa was scratched using a glass slide before snap freezing.

Insulin tolerance tests. Insulin tolerance tests (0.75 units/kg body weight, i.p.) were performed in unrestrained conscious male mice after a 4-h fast, and blood glucose was measured using an Accu-Check glucometer (Roche Diabetes Care).

Cell preparations. IECs were prepared from the upper (USL, corresponding to duodenum and jejunum) and lower (LSI, corresponding to ileum) small intestine, and the colon. Gut segments were incubated in chelating solution (15 mM EDTA, 1 mM DTT in PBS) for 30 min at 37 °C under shaking at 100 rpm. Isolated cells were pelleted, snap-frozen in liquid nitrogen, and stored at −80 °C until further protein and gene expression analyses. For isolation of lamina propria cells, mice were sacrificed and the ileum was removed from the mice, cleared from feces, fat tissue, and Peyer’s patches using HBSS without Ca2+ and Mg2+ containing 10 mM HEPES solution. Miltényi Lamina Propria Dissociation Kit for mouse was used to prepare epithelial and lamina propria cells. After passage through a 100 μm filter, the cell suspension was subjected to Percoll (GE Healthcare) density gradient of 40% and 80%, and the interface between the layers containing intraepithelial lymphocytes or lamina propria lymphocytes were collected. Fractions were then either suspended in PBS containing 2% FCS and 0.1% sodium azide before further FACS analyses, or snap-frozen for further RT-qPCR investigations.

Western blot analyses. IECs or gut mucosa scraping were solubilized at 4 °C in a lysis buffer “Tris-HCl 50 mM, NaCl 150 mM, EDTA 5 mM, Triton X-100 1%”) containing protease inhibitor (2x) (Complete table Easy pack, Roche) and phosphatases inhibitors (NaF 10 mM, Na3VO4 4 mM, Na2P04· 60 mM). Supernatants were collected after a 15-min centrifugation at 13,000 rpm at 4 °C. Proteins were quantified using the Bradford method (BioRad Protein Assay). The protein extracts were then subjected to SDS-PAGE electrophoresis and immunoblotted with the following primary antibodies: anti-pAkt (Ser473) (CST#4060), anti-Akt (CST#9272), anti-BiP (CST#3183), anti-CHOP (CST#5554), anti-NOD1 (CST#3187, Cell Signaling Technology), anti-p62 (P98860, Enzo BML), or anti-GAPDH (sc-25778, Santa Cruz Biotechnology). The immunoreactive bands were revealed using the Clarity Western ECL Substrate (Bio-RAD) Chemiluminescence, and analysis was performed with the ChemiDoc MP Imaging System (Bio-RAD).

RNA extraction and RT-qPCR analyses. Total RNAs were extracted from IECs using TRIzol® reagent (Life Technologies) according the manufacturer’s protocol, and 1 μg was used for reverse transcription (Life Technologies). cDNAs were amplified by qPCR (LightCycler® 480 SYBR Green I Master, Roche) using the primers described in the Supplementary Table 1. mRNA levels were normalized over the expression of GAPDH and TBP.

Intestinal permeability. Overnight fasted mice were submitted to an oral gavage of FITC-dextran 4 kDa (FD4, 0.6 mg/kg body weight) (TdB Consultancy) and 0.5% carboxymethycellulose solution including 6% Carmine red (Sigma) in order to evaluate gut transepithelial permeability. Normalized to intestinal transit. One hour after FD4 gavage,
peripheral blood was collected, and serum FITC-dextran concentrations were determined using a fluorescence spectrophotometer (Ex/Em 490/520 nm). The total intestinal transit time was measured by determination of the time between ingestion of carmine red and first appearance of the dye in feces.

**Histological analyses and histopathological scoring.** Gut samples from the proximal ileum and colon were fixed in 4% PFA, embedded in paraffin, and cut into 5 μm sections. After deparaffinization and rehydration, intestinal and colonic sections were stained using standard protocols with either hematoxylin-eosin (HE) or Alcian blue staining to evaluate mucus production. For Paneth cells immunolabelling, an anti-Lysozyme (Dako, EC.3.2.1.17, 1:200) primary antibody was used. Histopathological scoring was performed by blinded clinical evaluation using the following parameters [1]: severity of inflammation [2], ulceration depth [3], area involved in the ulcerative process [4], edema [5], vascular dilatation, and [6] ischemia, and parameter values were used to generate a «total histological score».

**Flow cytometry.** Ileal cells from the *laminia propria* were isolated using Lamina Propria Dissociation Kit (Miltenyi, 130-097-410) as previously described [25]. Each subset of *Lamina Propria Dissociation Kit* was stained using standard protocols with either hematoxylin-eosin (HE) or Alcian blue staining to evaluate mucus production. For Paneth cells immunolabelling, an anti-Lysozyme (Dako, EC.3.2.1.17, 1:200) primary antibody was used. Histopathological scoring was performed by blinded clinical evaluation using the following parameters [1]: severity of inflammation [2], ulceration depth [3], area involved in the ulcerative process [4], edema [5], vascular dilatation, and [6] ischemia, and parameter values were used to generate a «total histological score».

**Transmission electron microscopy.** Samples from LSI were analyzed under a JEOL 1011 transmission electron microscope with a Gatan Ertlangen CCD (charge-coupled device) camera. Acquisitions were processed using software «Digital Micrograph» and ImageJ.

**Microbiota analysis.** Bacterial DNA was extracted from luminal content samples using the ZR fecal DNA Miniprep kit (Zymo Research, USA). The *V3* region of 16S rDNA was amplified via flow cytometry after 20 min of staining at 4 °C in PBS containing 2% fetal bovine serum and 0.1% sodium azide with the following antibody combinations: CD45 (APC-Cy7, 30F11); CD64 (BV605, X54–57.1); Ly-6C (BV510, HK1.4); Ly-6G (PE, 1A8); CD11b (BV785, M1/70); CD11c (APC, N414); CD103 (BV421, M290); CXXCR1 (PE-CF594, SA011F11); F4/80 (PE-Cy7, BM8); CD16/32 (AF700, M5/114-5-2). Data acquisition was processed using Biosciences LSR Fortessa (BD Biosciences). Gating and calculation of cell population frequencies were computed with FlowJo (Tree Star) analysis software. Macrophages were identified as CD45<sup>+</sup> CD19<sup>-</sup> TCRγδ<sup>-</sup> TCRβ<sup>-</sup> CD11b<sup>+</sup> cells, DCs were identified as CD45<sup>+</sup> CD19<sup>-</sup> TCRγδ<sup>-</sup> TCRβ<sup>-</sup> CD11b<sup>+</sup> CD206<sup>-</sup> CD11c<sup>+</sup> cells, T cells were identified as CD45<sup>+</sup> CD19<sup>-</sup> TCRγδ<sup>-</sup> TCRβ<sup>-</sup> cells, and B cells were identified as CD45<sup>+</sup> TCRβ<sup>-</sup> CD19<sup>+</sup> cells. Gating strategies to determine macrophages, DC, T, and B cells are presented in Fig S1.

**Statistical analyses.** All values are presented as means ± SEM. Statistical analyses were performed with Prism software (Graph Pad V.8.3). Datasets were compared using non-parametric two-tailed Mann–Whitney U-test or analysis of variance (ANOVA) followed by Bonferroni post-test multiple comparisons. Statistical significance was assumed at *P* values < 0.05.

## 3. RESULTS

### 3.1. S961-associated insulin resistance compromises gut barrier integrity in lean mice

In order to determine the impact of blunted insulin signaling on gut barrier integrity independently of obesity, we developed a mouse model of inducible and reversible systemic insulin resistance. To that end, osmotic pumps delivering the IR antagonist S961, or PBS as control, were implanted subcutaneously for 7 days in C57Bl/6 J mice (S961 and PBS mice, respectively). The reversibility of S961-induced defects was in turn evaluated in S961 and PBS mice that were allowed a 7-day recovery time frame after removal of the pumps (revS961 and revPBS mice, respectively). As illustrated in Figure 1A, treatment with S961 was accompanied by a significant weight loss, which was totally rescued 1–2 days following pump removal. Of note, S961 infusion promptly triggered a sustained hyperglycemia, and cessation of the S961 treatment allowed a rapid drop in blood glucose concentrations that reached control levels within 3 days (Figure 1B). Accordingly, serum insulin concentrations were markedly enhanced in S961-treated mice and returned to control values in revS961 mice (Figure 1C), thereby reflecting impaired hepatic insulin clearance in the absence of functional IR [28]. Insulin tolerance tests (ITT) indicated the onset of a severe insulin resistance upon 7 days infusion with S961 (Figure 1D), whereas insulin sensitivity was fully restored and even improved 7 days following cessation of the treatment (Figure 1E). This was further illustrated by a lower glycemia in revS961 mice when compared to the revPBS control group at 60 min after i.p insulin challenge (Figure 1E). In line with these results, examination of IR downstream signaling in major insulin target tissues, such as liver and skeletal muscle, indicated that insulin-induced Akt phosphorylation was reduced upon S961 treatment and totally rescued in revS961 mice...
Figure 1: S961 induces global and reversible insulin resistance and enhances gut permeability in mice. (A) Kinetic of body weight loss and (B) post-prandial glycaemia in mice treated with PBS or S961 (20 nmol/wk) for 7 days (PBS, S961) through osmotic pump-mediated subcutaneous delivery (n = 8–16), or in mice studied during 7 days after pump removal (revPBS, revS961) (n = 4–8). (C) Portal insulin concentrations in 7-day PBS-or S961-treated mice that were fasted 4 h before refeeding overnight with 20% glucose (n = 7–8); (D) Insulin tolerance tests performed in PBS and S961 mice after 7 days of treatment (n = 12–16), or in revPBS and revS961 mice one week after pump removal (n = 8–11). (F–I) Western blot analyses and relative quantifications of Akt activation (P-Akt levels normalized to total Akt) in ileal (F, G) and colonic epithelial cells (H, I) in mice submitted in vivo to an i.p. pulse of insulin (5U/kg) for 10 min (n = 4). P-Akt and total Akt levels were first normalized to GAPDH on each corresponding blot (only GAPDH levels relative to total Akt blot are shown in F and H), and quantification of P-Akt/Akt levels (G, I) corresponds to the ratio of relative P-Akt/GAPDH levels on relative total Akt/GAPDH levels. (J) Intestinal permeability to FITC-dextran (FD4) (n = 4–8) and (K) plasma LBP concentrations (n = 8) in PBS and S961 mice after 7 days of treatment, or in revPBS and revS961 mice one week after pump removal. (A–E, G, I–K) Values are means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by ANOVA (B–C, G, I–K) or Mann–Whitney U-test (A, D–E).
following acute insulin pulse in vivo (Fig S2A–D). Of interest, S961 infusion similarly resulted in a striking reduction of insulin-driven Akt phosphorylation in epithelial cells from the ileum and the colon, while discontinuation of the treatment with S961 fully restored mucosal insulin signaling (Figure 1F–I).

While these data validated the reversible loss of downstream insulin signaling subsequent to transient S961 treatment, and further provided evidence that gut epithelium is an insulin sensitive organ, we next investigated the functional consequences of global insulin resistance per se (independently of obesity) on gut barrier integrity. In vivo gut permeability upon S961 treatment was evaluated through the measurement of FITC-dextran (FD4) transepithelial flux. One hour after oral gavage, plasma concentration of the FD4 tracer was significantly increased (2.7-fold) in S961-diabetic mice compared to PBS-treated mice (Figure 1J). Moreover, serum levels of LPS-binding protein (LBP), a surrogate marker of endotoxemia [11], was slightly, although not significantly, enhanced by S961 treatment (Figure 1K). Interestingly, similar values for both of these readouts of gut leakage were obtained in revS961 and control revPBS mice (Figure 1J–K), suggesting that the deleterious effects of insulin resistance and concomitant hyperglycemia on gut barrier function were reversible.

3.2 S961 treatment destabilizes epithelial cell junctions and promotes local inflammation

Since intercellular junctional complexes are critical components of epithelial integrity [29], we next performed histological as well as ultrastructural analyses of the gut epithelium from S961 and PBS-treated mice in order to explore the underlying mechanisms of S961-associated gut hyperpermeability. Of note, treatment with S961 did not cause any apparent histological defect in the ileum or in the colon, as shown on Fig S3A. However, a closer examination of the ileum through transmission electron microscopy (TEM) indicated that while tight and adherens junctions were classically observed in apical cell—cell contact regions of PBS mice, the epithelium of S961-diabetic mice appeared dramatically disorganized (Figure 2A). Notably, this was illustrated by the occurrence of cytosolic protrusions in the vicinity of intercellular spaces and brush border membranes, indicating loss of integrity of the epithelial cell monolayer (Figure 2A). In the colonic epithelium, cell—cell junctions were also disrupted following S961 treatment, as shown by enhanced spaces between adjacent cells and overflowing cytosolic contents at the apical membrane (Figure 2A). In accordance with these structural defects, the mRNA levels of genes encoding tight junction proteins (CLDN4, OCL, ZO1) were significantly decreased in ileal epithelial cells from mice treated with S961 for 7 days (Figure 2B), while only minor changes were observed at earlier time point (Fig S3B) or in the colonic epithelium of S961 mice, as compared to PBS-treated mice (Figure 2C).

We further examined whether those alterations of epithelial gut integrity upon S961-induced insulin resistance were associated with the onset of a low-grade inflammation. Despite the fact that S961 treatment triggered the disruption of gut mucosal barrier (Figure 1J–K) and the consecutive raise of capillary permeability, as documented by the 2.5-fold increase in albumin (66.5 kDa) released from blood vessels into the intestinal lumen (Figure 2D), this was not associated with systemic inflammation (Fig S3C). However, such a diabetic condition instead induced the onset of a slight intestinal inflammation, as shown by a 3-fold increase in lipocalin 2 fecal content and parallel unchanged neutrophil MPO activity (Figure 2E–F). Deeper evaluation of the cellular mechanisms underlying this local inflammatory state was performed by FACS analysis of immune cells populations isolated from the intestinal lamina propria of S961-treated mice. As compared to the PBS control group, S961-treated mice displayed an increased abundance of gut fully mature macrophages (CD11b+ CD206+) without changes in total CD11b+ macrophages (Figure 2G–H), dendritic cells, or in B and T lymphocytes relative number (Fig S3D–F), suggesting some alterations in gut innate immunity upon blockade of insulin signaling. Of note, among cytokines involved in IL-22-mediated barrier function and host defense, which were previously implicated in the susceptibility of obese and diabetic mice to infection [17,30], only IL23 mRNA levels were significantly increased by 3.7-fold in the intestinal lamina propria upon S961 challenge (Figure 2I). Together, these data indicate that the destabilization of intestinal epithelial cell junctions upon an acute S961-mediated insulin-resistant state only results in modest local inflammatory response.

3.3. Antibacterial activity of paneth cells is drastically impaired in S961-diabetic mice

By preventing bacterial adhesion and shaping the microbiome composition, mucus production by goblet cells and bacterial activity of Paneth cells represent major players in gut barrier maintenance [10]. Therefore, we next performed a kinetic study to explore whether these epithelial features could underlie increased gut permeability and related local inflammatory response in S961-diabetic mice treated for 3 or 7 days. A progressive reduction of ileal mRNA levels encoding specific goblet cell markers (Muc2, Tfr3, Gob5) was indeed observed following treatment with S961 (Figure 3A, S3A), while only minor significant changes were detected in the colon after 7 days of S961 infusion (Figure 3B), as compared to the PBS control group. Of note, parallel mucus staining with Alcian blue did not reveal any apparent modification in either the ileum or the colon during the S961-induced insulin resistant state, when compared to PBS-treated mice (Figure 3C).

Strikingly, quantification of Paneth cells markers, such as genes encoding antimicrobial peptides (Defa3, Defc5, Defa6, Ang4, Lyz), demonstrated that their expression was consistently reduced by at least 50% in the ileum of 7-day S961-treated mice (Figure 3D), while no significant alterations could be detected at earlier time point (Fig S4B). Supporting a drastic deterioration of bacterialic defense by Paneth cells upon S961-induced diabetic conditions, ileal lysozyme immunolabelling was significantly diminished in S961-treated mice when compared to the PBS control group (Figure 3E). Ultrastructural analyses by TEM further revealed that S961 infusion triggered profound alterations to the Paneth cells morphology (Figure 3F). This was illustrated by the presence of large cytosolic vacuoles with clear and filamentous contents, and by the reduction of secretory granules’ mean area and frequency in parallel with the appearance of abnormal thick and clear halos surrounding them (Figure 3F–H), consistent with the reduced fecal lysozyme content observed upon S961 treatment (Figure 3I).

While Paneth cells have been reported as highly prone to abnormalities upon altered unfolded protein response [31], swollen and distended endoplasmic reticulum (ER) cisterns in Paneth cells from S961-receiving mice were reminiscent of ER stress (Figure 3F). Western blot analyses of ER stress markers on ileal epithelial cells further revealed a trend towards enhanced CHOP protein levels in diabetic S961 mice when compared to the control PBS group, while BiP expression was comparable between the two groups (Fig S5). Of note, a significant decrease of NQO1 expression in ileal epithelial cells following S961 treatment suggested that intestinal ER-associated oxidative stress defense was impaired upon diabetic conditions.
Figure 2: S961 treatment triggers gut barrier defects and low-grade intestinal inflammation. (A) Representative electron microscopy of ileal and colonic samples from PBS- and S961-treated mice after 7 days of treatment. Scale bars: 2 μm (left panels: PBS, S961), 1 μm (right panels). White arrows indicate ultrastructural abnormalities. (B, C) Relative mRNA levels (normalized to Gapdh) of tight junction markers in isolated epithelial cells from the ileum (B) and the colon (C) of indicated groups of mice (n = 10–11). (D) Fecal albumin levels (n = 5), (E) fecal Lnc-2 content, (n = 4–5), and (F) ileal MPO activity (n = 9–14) measured in 7-day PBS- and S961-treated mice. (G, H) Flow cytometry analysis of macrophages in ileal lamina propria from the indicated groups of mice (n = 4–8). (I) Relative quantification of indicated cytokine mRNA levels in ileal lamina propria from 7-day PBS- and S961-treated mice (n = 6). (B–I) Values are means ± SEM. ns, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by ANOVA (B–C, I) or Mann–Whitney U-test (D–H).
Figure 3: S961 infusion decreased antimicrobial activity of Paneth cells. (A, B) Relative mRNA levels (normalized to Gapdh) of goblet cell markers in ileal and colonic IECs from 7-day PBS- and S961-treated mice (n = 10–11). (C) Representative Alcian blue staining of sections from the ileum (upper panels) and the colon (lower panels) of PBS and S961 mice. (D) Relative mRNA levels (normalized to Gapdh) of Paneth cell markers in ileal IECs from 7-day PBS- and S961-treated mice (n = 11). (E) Representative lysozyme immunostaining of ileal sections from PBS and S961 mice. (F) Representative electron microscopy images of ileal samples from PBS- and S961-treated mice. Scale bars: 1 μm (upper panels), part 2 μm (lower panels). (G, H) Mean secretory granule area and number of Paneth cells from PBS and S961 mice after 7 days of treatment (n = 3 mice per group). Data are means from 4 to 20 arbitrary chosen electron microscopy fields per mice, with 1–6 Paneth cells per field. (I) Fecal lysozyme activity in PBS and S961 mice after 7 days of treatment (n = 4–5). (A–B, D, G–I) Values are means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by ANOVA (A, B, D) or Mann–Whitney U-test (G–I).
3.4. Dysbiosis associated with S961 infusion induced intestinal barrier impairment

As bacterial activity of Paneth cells was impaired upon IR inhibition, we further investigated, through 16S rRNA gene sequencing, the potential consequences of S961 treatment on local microbiota equilibrium. Principal coordinate analysis using the Bray–Curtis distance and hierarchical clustering of luminal microbiota from the ileum of PBS- and S961-treated mice revealed that S961 treatment significantly altered the intestinal bacterial communities (Figure 4A, S5A). Three-day S961-challenged mice exhibited an intermediary profile when compared to the PBS control group and mice that received S961 for 7 days (Figure 4A, S5A). Moreover, cessation of S961 treatment allowed the rescue of an ileal microbial profile similar to PBS-infused mice (Figure 4A, S5A). A 7-day challenge with S961 triggered a reduction in ileal bacterial diversity (Figure 4B—C). While the ileal microbiota from the PBS control group was characterized, as previously described [32], by a large predominance of Firmicutes (above 90%), mice that were infused with S961 displayed an ileal bloom of pro-inflammatory Proteobacteria, in particular Enterobacteriaceae, at the expense of Bacteroidetes, Actinobacteria, and Firmicutes species (Figure 4D—E).

Of note, parallel analyses of the microbiota composition in the caecum of mice receiving S961 demonstrated that S961 treatment induced similar and reversible changes in the small and large intestines, as illustrated by a 20% increase in cecal Proteobacteria abundance when compared to the 7-day PBS-challenged control group (data not shown).

Interestingly, alterations of ileal and cecal microbiota composition upon 3 days of S961 treatment (Figure 4A—E, S5A) were not accompanied by major modifications in the expression of either tight junction (Fig S3B), goblet cells (Fig S4A) or Paneth cells markers (Fig S4A—B), suggesting that S961-induced dysbiosis preceded the profound epithelial defects that occurred after 7 days of insulin signal blockade (Figure 2A—B, 3A, 3D). In order to test whether microbiota imbalance could act as a triggering event in intestinal barrier disruption due to insulin resistance, 3-week-old specific-pathogen-free (SPF) C57BL/6 J mice were transplanted with feces from PBS- (PBS FT group) or S961-treated mice (S961 FT group), and comparative analyses were further performed 7 days later. Despite similar body weight and blood glucose of recipient mice regardless of donor (Fig S6B—C), the abundance of luminal Proteobacteria and Enterobacteriaceae was enhanced in the feces of S961 FT mice when compared to the PBS FT control group (Figure 4F—G), in accordance with the gut microbiota alterations previously observed in S961-treated mice (Figure 4D—E). Of note, S961 fecal transplantation paralleled induced the onset of gut hyperpermeability, as evidenced by the relative 2-fold increase of FITC-dextran plasma concentrations in S961 FT mice respective to PBS FT mice (Figure 4H). However, the transmission of the S961-associated ileal phenotype in mice that were transplanted with the fecal microbiota from an S961 donor was only partial. Indeed, S961 fecal transplantation was not associated with changes of fecal lipocalin activity, albumin content (Figure 4I—J), or mRNA levels of Paneth cell antimicrobial peptides, goblet cell markers, and genes encoding tight junction proteins (Fig S6D—F). Altogether, these results indicated that insulin resistance and associated hyperglycemia trigger the onset of a deleterious dysbiosis, as characterized by the rise of pro-inflammatory bacterial species, which consequently contribute at least in part to gut permeability impairment.

4. DISCUSSION

The systemic low-grade inflammation that characterizes obesity and associated insulin resistance and hyperglycemia was first considered to originate from the inflamed adipose tissue. However, more recent evidence has underscored the contribution of altered gut microbiota composition and increased intestinal permeability to this feature [11,33—35]. While most of these studies have focused on the gut defects associated with obesity in mice fed with high-calorie diets, we show in S961-treated mice that, independently of adiposity, insulin resistance and concomitant hyperglycemia per se are key players in the rapid onset of a drastic intestinal dysbiosis as well as major epithelial dysfunctions, including impaired bacterial defense by Paneth cells, enhanced gut permeability, and local low-grade inflammation. Moreover, we demonstrate that such imbalanced gut microbiota acts as an early initiating event of the intestinal epithelial defects upon insulin resistant states.

Gut microbial imbalance is a hallmark of various metabolic diseases, and the interaction of such dysbiotic microbiota with IEC was shown to play a pivotal role in the disruption of gut barrier integrity upon obesity [36,37]. While alterations of intestinal microbiota composition were previously also reported in lean and hyperglycemic mouse models of insulinopenia, those changes were shown not to directly affect intestinal permeability [17]. Accordingly, we demonstrate that, independently of obesity, S961-induced insulin resistance and associated hyperglycemia trigger drastic changes in both ileal and cecal microbiota composition. However, in contrast to the work by Thaiss et al., our study demonstrated that fecal transplant from S961-treated mice is sufficient to cause gut hyperpermeability, suggesting that microbiota imbalance consecutive to insulin resistance acts as one of the early triggers of intestinal barrier disruption. The protective role of proper insulin sensitivity on gut barrier integrity is also supported by the recent study by Rangan et al. [38]. Indeed, in a murine model of inflammatory bowel disease, intermittent fasting, which improves peripheral insulin sensitivity [39], was shown to alter microbiota composition by promoting the expansion of protective Lactobacillaceae and Bifidobacteriaceae, ultimately reducing systemic inflammation [38]. Furthermore, treating the mice with rosiglitazone, a PPARγ agonist that enhances insulin sensitivity in T2D patients, restored the defects induced by HFD on antimicrobial peptides expression and spatial distribution of microbiota in the ileum [40].

S961-induced ileal and cecal dysbiosis was characterized by a bloom of pro-inflammatory Proteobacteria and by a massive drop of obligate anaerobes abundance, concomitantly to the onset of a modest gut inflammation. Interestingly, obesity [41—43] and Crohn’s disease [44,45] were previously associated with enrichment in fecal Proteobacteria. Among possible mechanisms underlying the onset of such a dysbiosis subsequently to defective insulin action, changes in host physiology, as observed following antibiotic treatment or infection with enteric pathogen, may increase oxygen availability and drive luminal expansion of Enterobacteriaceae [46]. While oxidative metabolism of colonocytes normally maintains epithelial hypoxia and favors a microbial community dominated by obligate anaerobic bacteria, reduced beta-oxidation capacities of IECs upon intestinal inflammation were shown to increase oxygen availability and to consequently promote dysbiosis and associated burst of Proteobacteria [47,48]. Moreover, the downregulation of PPAR-γ signaling, as observed in diabetic insulin-deficient mice [49], was shown to increase host nitrate production, the exploitation of which by commensal Enterobacteriaceae promotes their predominance upon inflammatory conditions [50]. Altogether, these reports suggest that, in our model, insulin resistance may trigger metabolic alterations in ileal epithelial cells thereby hampering the delicate balance between the host and resident microbial communities. Nevertheless, our data indicate that the ileal blooming of Proteobacteria within 3 days of S961 treatment did not parallel major defects in various components of
the gut barrier, indicating that dysbiosis might instead initiate epithelial dysfunctions upon insulin resistance. Further fecal transfer experiments from S961-treated mice indeed confirmed that S961-dysbiotic microbiota was sufficient to alter gut permeability. Accordingly, a direct deleterious effect of imbalanced microbiota on cell—cell junction integrity was previously demonstrated upon antibiotics treatment [51]. However, mice that were transplanted with the fecal microbiota from S961 donor did not display any significant quantitative change in mRNA encoding tight junction proteins, suggesting that transplantation of fecal instead of ileal or cecal microbiota from S961 donor mice might not be sufficient to achieve the complete restoration of the S961-associated ileal phenotype. Commensal microbiota is a reservoir of bacterial endotoxins that translocate into the systemic circulation upon intestinal barrier impairment.
disruption to induce metabolic endotoxemia. Under steady state conditions, intestinal epithelium forms a selective barrier allowing the transcellular transport of nutrients while rigorously excluding the paracellular flow of immune-stimulatory bacterial products across the epithelium. Tight connections between IECs through intercellular junctions actively contribute to the physical component of the gut barrier. Upon S961 treatment, global IR signaling blockade and associated hyperglycemia induced a dramatic disorganization of IECs’ brush border and a breakdown of intercellular junctions in the ileum. Of note, impairment of IEC junctions was previously documented upon obese and diabetic states, in both humans [5,52,53] and animal models [14,54–56]. Moreover, recent studies demonstrated that, independently of obesity, both hyperglycemia, via a transcriptional reprogramming mediated by intestinal glucose metabolism [17], and blunted intestinal insulin signaling, via a FoxO-dependent mechanism, control the integrity of IEC intercellular junctions [57].

Among other components of the gut barrier, Paneth and goblet cells occupy a key position, as the antimicrobial peptides and the mucus they produce contribute to the host protection from enteric pathogens and bacterial translocation to the regulation of commensal microbiota composition, and local immune response. We report in this study that S961 infusion impaired intestinal bactericidal defense by Paneth cells, which likely resulted from the profound structural alterations we observed in parallel in this epithelial cell type. In accordance with this observation, a defective antimicrobial activity was previously described upon insulin-resistant state in mouse models of high-fat diet induced obesity or STZ-mediated insulinopenia [58,59]. Interestingly, ultrastructural analyses further revealed that, upon S961 treatment, Paneth cells displayed major abnormalities, including reduced number and aberrant morphology of secretory granules as well as apparent features of ER stress. Of note, reduced expression of antimicrobial peptides and activation of the unfolded protein response were reported in Paneth cells of obese patients [60]. However, molecular analyses of ileal tissue from S961-treated mice did not reveal any significant modification of the unfolded stress response, to which Paneth cells were shown to be highly sensitive in mice [31]. Our data therefore suggest either the involvement of other mechanisms downstream of IR blockade in Paneth cells disruption or underline the need to perform further analyses on purified intestinal crypts or sorted Paneth cells. Besides hampering bactericidal defenses, S961-associated insulin resistance affected the intestinal but not the colonic expression of goblet cell markers. Despite the fact that this was not correlated with apparent changes of epithelial mucus staining, hyperglycemia was previously associated with decreased bacterial-epithelial distance in the colon [61], supporting the contribution of impaired goblet cell secretion to barrier dysfunction upon an insulin resistant state. Accordingly, Wei et al. previously reported that a 12-day treatment with insulin in a diabetic mouse model was sufficient to restore the thickness of the colonic mucus layer and to correct associated intestinal gut hyperpermeability [18]. While the lowered expression of the fatty acid synthase (Fas), due to impaired gut insulin action, was suggested to reduce both expression and palmitoylation of the mucin Muc2 and its subsequent luminal secretion, intestinal mRNA quantification of prototropic hepatic insulin target genes encoding lipogenic enzymes (Acc, Fas, Scd1) revealed only a significant decrease of the desaturase Scd1 upon S961 challenge (data not shown). However, unchanged expression of Muc2 in mice with targeted deletion of Scd1 in the intestinal epithelium [62] suggests the involvement of other signaling pathways downstream of IR blockade in the reduced expression of goblet cell markers. Alternatively, the high vulnerability of goblet cells to ER stress that was observed in intestinal XBP1 KO mice [63] as well as in diet-induced obesity mice model [64] might prompt further investigation in order to determine whether insulin resistance triggers ER stress in goblet cells.

Besides triggering gut dysbiosis and enhanced intestinal permeability, S961-induced insulin resistance promotes a local immune response that was illustrated by the ileal accumulation of fully mature CD11b+ CD206+ macrophages [65] and the significant increase of IL23 mRNA expression in the ileum lamina propria of S961-treated mice, consistent with previous report [25]. Accordingly, macrobe-associated molecular patterns were shown to stimulate the production of IL23 by macrophages and dendritic cells upon pathogen invasion or intestinal barrier breach [66], and comprehensive analyses in human showed that IL23 mRNA levels were enhanced in combined lamina propria and epithelial fraction of jejunum from obese patients compared to lean subjects [67]. Of note, IL23 was involved in the initiation and perpetuation of both innate and T cell-mediated intestinal inflammation in various mouse models of colitis, and blockade or genetic ablation of IL23 was found to attenuate intestinal inflammation [68]. Moreover, CD11b+ macrophages, which are highly bactericidal, were shown to produce high quantities of IL-23 at the early stages of colitis and to be essential for the initiation of intestinal immunopathology [69,70]. While a higher risk of infection by enteropathogens was reported in db/db or high-fat-diet fed obese and diabetic mice, in STZ-treated diabetic mice [17] as well as in diabetic patients [71], rescuing the compromised production of IL23 in obese mice after Citrobacter rodentium infection was sufficient to restore the mucosal host defense [30]. According with these observations, the blockade of insulin signaling by S961 treatment in mice were associated with enhanced susceptibility to enteric infection by C. rodentium (data not shown), suggesting that activation of the IL23-to-IL22 axis upon enteric infection might be defective during diabetes, independently of obesity.

In conclusion, this study highlights insulin signaling as an indispensable gatekeeper of gut barrier integrity and as a safeguard against local inflammation. Independent of obesity, insulin resistance and associated hyperglycemia trigger a rapid, drastic, and reversible intestinal dysbiosis, which contributes at least partly to enhanced gut permeability. Moreover, we demonstrate that insulin sensitivity is a key player in the maintenance of functional gut epithelial barrier major components, as illustrated by disrupted cell—cell adhesion, as well as the breakdown of mucus and antimicrobial peptides production upon S961 treatment. Altogether, our data suggest that, besides enhanced adiposity, the detrimental consequences of global insulin resistance on the gut epithelium and associated microbiota might contribute to the onset of chronic low-grade systemic inflammation and the increased risk of acute enteric infections during metabolic syndrome.

**AUTHORS’ CONTRIBUTION**

AFB, SG, and DG designed and directed the project. DG, MC, VF, FB, WC, LB, MR, FS, GB, AFB, and SG carried out the experiment and performed the analysis. AFB, SG, DG, MC, GB, and AL drafted the manuscript and designed the figures.

**ACKNOWLEDGEMENTS**

We would like to thank Dr Laurge Schäffer (Novo Nordisk, Copenhagen) for the kind gift of S961, Dr Latif Rachdi (Cochin Institute, Paris) for helpful collaboration for the first S961 experiments, and Dr Patricio Serradas, Dr Agnès Ribeiro, and Léa Le Gléau (Nutròmics, Paris) for their help in the fecal microbiota transplantation experiment. We thank the animal facility staff at the Institut Cochin and the RPPA at Paris-
Sorbonne University, and the core facilities at the Cochin Institute: HistIM and Electronic Microscopy. We also thank Gwenaëlle Randuaine (INRAE, Rennes) for help in microbiota analyses. Our laboratory is supported by grants from the National Agency for Research (ANR) (ANR-20-CE14-0044-01), the Foundation for Medical Research (FMR) (DE020150331744), the French Diabetes Society (SFD) (Research grant SFD - Roche Diabetes Care), the European Foundation for the study of Diabetes (EFSO) (EFSO/Nordov Kost seeking for the same amount of money - 94899), the Idex Université de Paris (Emergence in research grant), the Cochin Institute (inter-group project grant), and the hospital University Department DHU AUTHORS (Autoimmune and HORMonal disease) (Young researcher grant).

CONFLICT OF INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2022.101438.

REFERENCES

[1] Gregor, M.F., Hotamisligil, G.S., 2011. Inflammatory mechanisms in obesity. Annual Review of Immunology 29:415–445.

[2] Wellen, K.E., Hotamisligil, G.S., 2005. Obesity, inflammation, stress, and diabetes. Journal of Clinical Investigation 115:1111–1119.

[3] Teixeira, T.F., Collado, M.C., Ferreira, C.L., Bressan, J., Peluzio Mdo, C., 2012. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity 21:E607–E615.

[4] Genser, L., Aguanno, D., Soula, H.A., Dong, L., Tryster, I., Assmann, K., et al., 2011. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. The Journal of Pathology 246:217–230.

[5] Dalmas, E., Rouault, C., Abdennour, M., Roviere, C., Rizkilla, S., Bar-Hen, A., et al., 2011. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. The American Journal of Clinical Nutrition 94:450–458.

[6] Calder, P.C., Aihualalia, N., Brouns, F., Buettler, T., Clement, K., Cunningham, K., et al., 2011. Dietary factors and low-grade inflammation in relation to overweight and obesity. British Journal of Nutrition 106(Suppl 3):S5–S78.

[7] Grant, R.W., Dinti, V.D., 2015. Adipose tissue as an immunological organ. Obesity 23:512–518.

[8] Cox, A.J., West, N.P., Cripps, A.W., 2015. Obesity, inflammation, and the gut microbiota. Lancet Diabetes & Endocrinology 3:207–215.

[9] Peterson, L.W., Artis, D., 2014. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nature Reviews Immunology 14:141–153.

[10] Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Kraut, C., Bastelica, D., et al., 2007. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772.

[11] Clemente-Postigo, M., Oliva-Olivera, W., Coin-Araguez, L., Ramos-Molina, B., Giraldez-Perez, R.M., Lhamyani, S., et al., 2019. Metabolic endotoxemia promotes adipose dysfunction and inflammation in human obesity. American Journal of Pathology. Endocrinology and Metabolism 316:E319–E332.

[12] Miele, L., Valenza, V., La Torre, G., Mantello, M., Cammarota, G., Ricci, R., et al., 2009. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:1877–1887.

[13] Cani, P.D., Bibiloni, R., Kraut, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., et al., 2008. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:1470–1481.

[14] Araujo, J.R., Tomas, J., Brenner, C., Sansonetti, P.J., 2017. Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity. Biochimie 141:97–106.

[15] Winer, D.A., Luck, H., Tsai, S., Winer, S., 2016. The intestinal immune system in obesity and insulin resistance. Cell Metabolism 23:413–426.

[16] Thais, C.A., Levy, M., Groshева, I., Zheng, D., Soffer, E., Blacher, E., et al., 2018. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science 359:1376–1383.

[17] Wei, X., Yang, Z., Rey, F.E., Ridaura, V.K., Davidson, N.O., Gordon, J.I., et al., 2012. Fatty acid synthase modulates intestinal barrier function through palmitoylation of mucin 2. Cell Host & Microbe 11:140–152.

[18] Yu, S., Tong, K., Zhao, Y., Balasubramanian, L., Yap, G.S., Ferraria, R.P., et al., 2018. Paneth cell multipotency induced by notch activation following injury. Cell Stem Cell 23:46–59 e45.

[19] Rosokawa, M., Dolci, W., Thorens, B., 2001. Differential sensitivity of GLUT1- and GLUT2-expressing beta cells to streptozotocin. Biochemical and Biophysical Research Communications 289:1114–1117.

[20] Miyamoto, K., Hase, K., Taketani, Y., Minami, H., Oka, T., Nakabou, Y., et al., 1991. Diabetes and glucose transporter gene expression in rat small intestine. Biochemical and Biophysical Research Communications 181:1110–1117.

[21] Leturque, A., Brot-Laroche, E., Le Gall, M., 2009. GLUT2 mutations, translocation, and receptor function in diet sugar managing. American Journal of Physiology. Endocrinology and Metabolism 296:E985–E992.

[22] Lengeler, J., 1980. Analysis of the physiological effects of the antibiotic streptozotocin on Escherichia coli K 12 and other sensitive bacteria. Archives of Microbiology 128:196–203.

[23] Gusarov, V., Alexa, C.A., Na, E., Stevis, P.E., X, Y., Bonner-Weir, S., et al., 2014. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell 159:691–696.

[24] Rouland, M., Beaudoin, L., Rouxel, O., Bertrand, L., Cagninacci, L., Safranin, A., et al., 2022. Gut mucosa alterations and loss of segmented filamentous bacteria in type 1 diabetes are associated with inflammation rather than hyperglycaemia. Gut 71:296–308.

[25] Escudie, F., Auer, L., Bernard, M., Mariassou, M., Cauquil, L., Vidal, K., et al., 2018. FROGS: find, rapidly, OTUs with galaxy solution. Bioinformatics 34:1287–1294.

[26] Le Roy, T., Debedat, J., Marquet, F., Da-Cunha, C., Ichou, F., Guerre-Millo, M., et al., 2018. Comparative evaluation of microbiota engraftment following fecal microbiota transfer in mice models: age, kinetic and microbial status matter. Frontiers in Microbiology 9:3289.

[27] Michael, M.D., Kulkami, R.N., Postic, C., Previs, S.F., Shulman, G.I., Magnuson, M.A., et al., 2000. Loss of insulin signaling in hepatocytes leads to severe insulin resistance, diabetes, and progressive hepatic dysfunction. Molecular Cell 6:87–98.

[28] Wolfs, C., Emsley, R., 2013. The composition of the gut microbiota shapes the human immune system. PLoS One 8:e647.

[29] Bemark, M., et al., 2015. The composition of the gut microbiota shapes the human immune system. PLoS One 5:e12191.
Marchiando, A.M., Graham, W.V., Turner, J.R., 2010. Epithelial barriers in colorectal cancer. The Journal of Nutritional Biochemistry 23:1207–1213.

Winer, S., Paltser, G., Chan, Y., Tsui, H., Engleman, E., Winer, D., et al., 2009. Obesity predisposes to Th17 bias. European Journal of Immunology 39:2629–2635.

Cani, P.D., Ost, M., Geurts, L., Everard, A., 2012. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3:279–288.

Gin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., et al., 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60.

Rangan, P., Choi, I., Wei, M., Navarrete, G., Guen, E., Brandhorst, S., et al., 2019. Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology. Cell Reports 26:2704–2719 e2706.

Fabbiano, S., Suarez-Zamorano, N., Chevalier, C., Lazarevic, V., Kieser, S., Rigo, D., et al., 2016. Functional gut microbiota remodeling contributes to the caloric restriction-induced metabolic improvements. Cell Metabolism 28:907–921 e907.

Tommas, J., Mulet, C., Safarian, A., Cavin, J.B., Ducroc, R., Regnaudt, B., et al., 2016. High-fat diet modifies the PPAR-gamma pathway leading to disruption of microbial and physiological ecosystem in murine small intestine. Proceedings of the National Academy of Sciences of the United States of America 113:E5934–E5943.

Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031.

Lambeth, S.M., Carson, T., Lowe, J., Ramaraj, T., Leff, J.W., Luo, L., et al., 2015. Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. Journal of Diabetes, Obesity & Metabolism 2:1–7.

Fei, N., Zhao, L., 2013. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. The ISME Journal 7:880–884.

Garrett, W.S., Gallini, C.A., Yatsunenko, T., Michaud, M., DuBois, A., Delaney, M.L., et al., 2010. Enterobacteriaceaeae act in concert with the gut microbiota to induce spontaneous and maternally transmitted collins. Cell Host & Microbe 8:292–300.

Huttenhower, C., Kostic, A.D., Xavier, R.J., 2014. Inflammatory bowel disease as a model for translating the microbiome. Immunity 40:843–854.

Rivera-Chavez, F., Lopez, C.A., Baumlert, A.J., 2017. Oxygen as a driver of gut dysbiosis. Free Radical Biology and Medicine 105:93–101.

Hughes, E.R., Winter, M.G., Duerkop, B.A., Spiga, L., Furtado de Carvalho, T., Mehta, R., et al., 2015. Microbial respiration and formate oxidation as metabolic signatures of inflammation-associated dysbiosis. Cell Host & Microbe 21:208–219.

Litvak, Y., Byrdloss, M.K., Baumlert, A.J., 2018. Colonocyte metabolism shapes the gut microbiota. Science 362.

Vidal-Puig, A., Jimenez-Linan, M., Lowell, B.B., Hamann, A., Hu, E., Spiegelman, B., et al., 1996. Regulation of PPAR gamma gene expression by obesity. Cell 87:2719 e2706.

Kaser, A., Lee, A.H., Franke, A., Glickman, J.N., Zeissig, S., Tilg, H., et al., 2017. Diversity and functions of microbial and physiological ecosystem in murine small intestine. Proceedings of the National Academy of Sciences of the United States of America 113:E5934–E5943.

Zhou, H., Zhou, S.Y., Gillilland III, M., Li, J.Y., Lee, A.H., Gao, J., et al., 2020. Diversity and functions of microbial and physiological ecosystem in murine small intestine. Proceedings of the National Academy of Sciences of the United States of America 113:E5934–E5943.